These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2500956)

  • 1. Antibody response to the viral negative factor (nef) in HIV-1 infection: a correlate of levels of HIV-1 expression.
    Reiss P; de Ronde A; Lange JM; de Wolf F; Dekker J; Debouck C; Goudsmit J
    AIDS; 1989 Apr; 3(4):227-33. PubMed ID: 2500956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals.
    Reiss P; de Wolf F; Kuiken CL; de Ronde A; Dekker J; Boucher CA; Debouck C; Lange JM; Goudsmit J
    J Acquir Immune Defic Syndr (1988); 1991; 4(2):165-72. PubMed ID: 1898969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to the nef protein and to nef peptides in HIV-1-infected seronegative individuals.
    Ameisen JC; Guy B; Chamaret S; Loche M; Mouton Y; Neyrinck JL; Khalife J; Leprevost C; Beaucaire G; Boutillon C
    AIDS Res Hum Retroviruses; 1989 Jun; 5(3):279-91. PubMed ID: 2786420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of synthetic peptides for the detection of antibodies against the nef regulating protein in sera of HIV-infected patients.
    Sabatier JM; Clerget-Raslain B; Fontan G; Fenouillet E; Rochat H; Granier C; Gluckman JC; Van Rietschoten J; Montagnier L; Bahraoui E
    AIDS; 1989 Apr; 3(4):215-20. PubMed ID: 2500954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody response to the negative regulatory factor (nef) in experimentally infected macaques: correlation with viremia, disease progression, and seroconversion to structural viral proteins.
    Kirchhoff F; Voss G; Nick S; Stahl-Hennig C; Coulibaly C; Frank R; Jentsch KD; Hunsmann G
    Virology; 1991 Jul; 183(1):267-72. PubMed ID: 1675823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low antigenicity of HIV-1 rev: rev-specific antibody response of limited value as correlate of rev gene expression and disease progression.
    Reiss P; De Ronde A; Lange JM; De Wolf F; Dekker J; Danner SA; Debouck C; Goudsmit J
    AIDS Res Hum Retroviruses; 1989 Dec; 5(6):621-8. PubMed ID: 2692659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection.
    Cheingsong-Popov R; Panagiotidi C; Bowcock S; Aronstam A; Wadsworth J; Weber J
    BMJ; 1991 Jan; 302(6767):23-6. PubMed ID: 1899349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1.
    Reiss P; Lange JM; de Ronde A; de Wolf F; Dekker J; Debouck C; Goudsmit J
    J Med Virol; 1990 Mar; 30(3):163-8. PubMed ID: 2341832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appearance of predictors of disease progression in relation to the development of AIDS.
    de Wolf F; Lange JM; Houweling JT; Mulder JW; Beemster J; Schellekens PT; Coutinho RA; van der Noordaa J; Goudsmit J
    AIDS; 1989 Sep; 3(9):563-9. PubMed ID: 2571348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-nef antibodies and other predictors of disease progression in HIV-1 seropositive injecting drug users.
    Rezza G; Titti F; Pezzotti P; Sernicola L; Lo Caputo S; Angarano G; Lazzarin A; Sinicco A; Rossi GB; Verani P
    J Biol Regul Homeost Agents; 1992; 6(1):15-20. PubMed ID: 1359736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low or no antibody responses to human immunodeficiency virus type 1 Nef in infected carriers with subtype E, in contrast to subtype B that showed antibodies preferentially recognizing subtype-specific Nef epitopes.
    Komoto S; Kinomoto M; Ibrahim MS; Zhong Q; Auwanit W; Ayuthaya PI; Otake T; Mori H; Oishi I; Kurosu T; Takahashi H; Mukai T; Ikuta K
    Vaccine; 2001 Apr; 19(20-22):3019-32. PubMed ID: 11282214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An ELISA-inhibition assay for antibody to human immunodeficiency virus core antigen (p24).
    Povolotsky J; Gold JW; Darminin P; Chein N; Baron P; Armstrong D
    J Virol Methods; 1990 Oct; 30(1):109-14. PubMed ID: 2128300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to recombinant HIV-1 nef protein detected in HIV-1 infection as well as in nonrisk individuals.
    Ranki A; Järvinen K; Valle SL; Nurmilaakso P; Krohn K
    J Acquir Immune Defic Syndr (1988); 1990; 3(4):348-55. PubMed ID: 2179525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of anti-nef antibody detection as an early serologic marker of human immunodeficiency virus infection.
    Bahraoui E; Benjouad A; Sabatier JM; Allain JP; Laurian Y; Montagnier L; Gluckman JC
    Blood; 1990 Jul; 76(1):257-64. PubMed ID: 1694699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of HIV and its implications for serodiagnosis and monitoring of antiviral therapy.
    Goudsmit J; Lange JM; Krone WJ; Teunissen MB; Epstein LG; Danner SA; van den Berg H; Breederveld C; Smit L; Bakker M
    J Virol Methods; 1987 Aug; 17(1-2):19-34. PubMed ID: 3478346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of human immunodeficiency virus (HIV) p24 antigenemia with decrease in CD4+ lymphocytes and onset of acquired immunodeficiency syndrome during the early phase of HIV infection.
    Rinaldo C; Kingsley L; Neumann J; Reed D; Gupta P; Lyter D
    J Clin Microbiol; 1989 May; 27(5):880-4. PubMed ID: 2501352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibodies as a prognostic indicator in the progression of acquired immune deficiency syndrome (AIDS)-related disorders: a double-blind study.
    Sei Y; Tsang PH; Roboz JP; Sarin PS; Wallace JI; Bekesi JG
    J Clin Immunol; 1988 Nov; 8(6):464-72. PubMed ID: 3146584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliable confirmation of antibodies to human immunodeficiency virus type 1 (HIV-1) with an enzyme-linked immunoassay using recombinant antigens derived from the HIV-1 gag, pol, and env genes.
    Ng VL; Chiang CS; Debouck C; McGrath MS; Grove TH; Mills J
    J Clin Microbiol; 1989 May; 27(5):977-82. PubMed ID: 2787334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies to HIV-1 nef(p27): prevalence, significance, and relationship to seroconversion.
    Cheingsong-Popov R; Panagiotidi C; Ali M; Bowcock S; Watkins P; Aronstam A; Wassef M; Weber J
    AIDS Res Hum Retroviruses; 1990 Sep; 6(9):1099-105. PubMed ID: 2265027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of antibodies to the core protein P17, a serological marker during HIV-1 infection.
    Mehta SU; Rupprecht KR; Hunt JC; Kramer DE; McRae BJ; Allen RG; Dawson GJ; Devare SG
    AIDS Res Hum Retroviruses; 1990 Apr; 6(4):443-54. PubMed ID: 1692727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.